Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 studyArjun Vasant Balar, Ronald de Wit, Joost L. Boormans et al.|The Lancet Oncology|2021Cited by 532
Development, multi-institutional external validation, and algorithmic audit of an artificial intelligence-based Side-specific Extra-Prostatic Extension Risk Assessment tool (SEPERA) for patients undergoing radical prostatectomy: a retrospective cohort studyJethro C.C. Kwong, Alexandre R. Zlotta, Adree Khondker et al.|The Lancet Digital Health|2023Cited by 16